NASDAQ: BCDA - BioCardia, Inc.

Yield per half year: +611.15%
Sector: Healthcare

Share chart BioCardia, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About

BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease.

More details
The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

Выручка 0.00071
EBITDA -0.014
Число акций ао 0.02118 млрд
P/S 31.8
P/BV 9.53
EV/EBITDA -1.29
Цена ао 0.42
ISIN US09060U5074
Сайт https://www.biocardia.com
Валюта usd
IPO date 2008-03-14
Sector Health Care
Industry Biotechnology
Валюта отчета usd
Change price per day: -0.5907% (2.81)
Change price per week: -4.99% (2.94)
Change price per month: +11.74% (2.5)
Change price per 3 month: -4.01% (2.91)
Change price per half year: +611.15% (0.3928)
Change price per year: +598.35% (0.4)
Change price per 3 year: -16.61% (3.35)
Change price per 5 year: -41.19% (4.75)
Change price per year to date: +194.04% (0.95)
All parameters

Underestimation

Title Value Grade
P/S 28.86 1
P/BV -8.59 0
P/E 0 0
EV/EBITDA -1.24 0
Total: 3.38

Efficiency

Title Value Grade
ROA, % -387.38 0
ROE, % 721.83 10
Total: 3.33

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 1.43

Debt

Title Value Grade
Debt/EBITDA -0.1171 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % -32.82 0
Yield Ebitda, % -19.76 0
Yield EPS, % 211.59 10
Total: 2.2
More

Institutions Volume Share, %
CM Management, LLC 700000 14.44
Vanguard Group Inc 650763 13.42
Geode Capital Management, LLC 159648 3.29
Renaissance Technologies, LLC 88300 1.82
Family Management Corporation 77500 1.6
Susquehanna International Group, LLP 65426 1.35
Blackrock Inc. 42767 0.88
Virtu Financial LLC 41348 0.85
Citadel Advisors Llc 33629 0.69
Brown Advisory Inc. 33085 0.68



Head Job title Payment Year of birth
Dr. Peter A. Altman Ph.D. CEO, President & Director 515.51k 1967 (57 years)
Mr. David McClung Chief Financial Officer 370.86k 1963 (61 year)
Mr. Edward M. Gillis Senior Vice President of Devices 263.1k 1962 (62 years)

Address: United States, Sunnyvale. CA, 320 Soquel Way - open in Google maps, open in Yandex maps
Website: https://www.biocardia.com